vs
ANI PHARMACEUTICALS INC（ANIP）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是LiveRamp Holdings, Inc.的1.2倍（$247.1M vs $212.2M），LiveRamp Holdings, Inc.净利率更高（18.8% vs 11.1%，领先7.7%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 8.6%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 11.1%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
ANIP vs RAMP — 直观对比
营收规模更大
ANIP
是对方的1.2倍
$212.2M
营收增速更快
ANIP
高出21.1%
8.6%
净利率更高
RAMP
高出7.7%
11.1%
两年增速更快
ANIP
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $212.2M |
| 净利润 | $27.5M | $39.9M |
| 毛利率 | — | 71.9% |
| 营业利润率 | 14.1% | 18.6% |
| 净利率 | 11.1% | 18.8% |
| 营收同比 | 29.6% | 8.6% |
| 净利润同比 | 367.5% | 255.7% |
| 每股收益（稀释后） | $1.14 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPRAMP
| Q4 25 | $247.1M | $212.2M | ||
| Q3 25 | $227.8M | $199.8M | ||
| Q2 25 | $211.4M | $194.8M | ||
| Q1 25 | $197.1M | $188.7M | ||
| Q4 24 | $190.6M | $195.4M | ||
| Q3 24 | $148.3M | $185.5M | ||
| Q2 24 | $138.0M | $176.0M | ||
| Q1 24 | $137.4M | $171.9M |
净利润ANIPRAMP
| Q4 25 | $27.5M | $39.9M | ||
| Q3 25 | $26.6M | $27.4M | ||
| Q2 25 | $8.5M | $7.7M | ||
| Q1 25 | $15.7M | $-6.3M | ||
| Q4 24 | $-10.3M | $11.2M | ||
| Q3 24 | $-24.2M | $1.7M | ||
| Q2 24 | $-2.3M | $-7.5M | ||
| Q1 24 | $18.2M | $-5.4M |
毛利率ANIPRAMP
| Q4 25 | — | 71.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.1% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | — | 71.9% | ||
| Q3 24 | — | 72.4% | ||
| Q2 24 | — | 70.6% | ||
| Q1 24 | — | 72.2% |
营业利润率ANIPRAMP
| Q4 25 | 14.1% | 18.6% | ||
| Q3 25 | 15.9% | 10.7% | ||
| Q2 25 | 6.6% | 3.7% | ||
| Q1 25 | 13.3% | -6.1% | ||
| Q4 24 | -2.3% | 7.5% | ||
| Q3 24 | -13.8% | 4.0% | ||
| Q2 24 | 3.7% | -3.0% | ||
| Q1 24 | 14.8% | -8.3% |
净利率ANIPRAMP
| Q4 25 | 11.1% | 18.8% | ||
| Q3 25 | 11.7% | 13.7% | ||
| Q2 25 | 4.0% | 4.0% | ||
| Q1 25 | 8.0% | -3.3% | ||
| Q4 24 | -5.4% | 5.7% | ||
| Q3 24 | -16.3% | 0.9% | ||
| Q2 24 | -1.7% | -4.3% | ||
| Q1 24 | 13.2% | -3.1% |
每股收益（稀释后）ANIPRAMP
| Q4 25 | $1.14 | $0.62 | ||
| Q3 25 | $1.13 | $0.42 | ||
| Q2 25 | $0.36 | $0.12 | ||
| Q1 25 | $0.69 | $-0.10 | ||
| Q4 24 | $-0.45 | $0.17 | ||
| Q3 24 | $-1.27 | $0.03 | ||
| Q2 24 | $-0.14 | $-0.11 | ||
| Q1 24 | $0.82 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $403.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $962.3M |
| 总资产 | $1.4B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPRAMP
| Q4 25 | $285.6M | $403.4M | ||
| Q3 25 | $262.6M | $376.9M | ||
| Q2 25 | $217.8M | $371.1M | ||
| Q1 25 | $149.8M | $420.8M | ||
| Q4 24 | $144.9M | $384.3M | ||
| Q3 24 | $145.0M | $348.4M | ||
| Q2 24 | $240.1M | $342.7M | ||
| Q1 24 | $228.6M | $368.9M |
股东权益ANIPRAMP
| Q4 25 | $540.7M | $962.3M | ||
| Q3 25 | $505.8M | $943.8M | ||
| Q2 25 | $436.8M | $947.8M | ||
| Q1 25 | $418.6M | $948.9M | ||
| Q4 24 | $403.7M | $957.7M | ||
| Q3 24 | $405.9M | $932.1M | ||
| Q2 24 | $455.8M | $951.9M | ||
| Q1 24 | $452.0M | $949.1M |
总资产ANIPRAMP
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $920.8M | $1.2B | ||
| Q1 24 | $914.5M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | — |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPRAMP
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | $57.4M | ||
| Q2 25 | $75.8M | $-15.8M | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $15.9M | $45.1M | ||
| Q3 24 | $12.5M | $55.6M | ||
| Q2 24 | $17.4M | $-9.3M | ||
| Q1 24 | $18.3M | — |
自由现金流ANIPRAMP
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $56.8M | ||
| Q2 25 | $71.8M | $-16.2M | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | $44.8M | ||
| Q3 24 | $7.7M | $55.4M | ||
| Q2 24 | $13.0M | $-9.6M | ||
| Q1 24 | $13.7M | — |
自由现金流率ANIPRAMP
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | 28.4% | ||
| Q2 25 | 34.0% | -8.3% | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | 22.9% | ||
| Q3 24 | 5.2% | 29.8% | ||
| Q2 24 | 9.4% | -5.4% | ||
| Q1 24 | 10.0% | — |
资本支出强度ANIPRAMP
| Q4 25 | 0.5% | 0.1% | ||
| Q3 25 | 2.7% | 0.3% | ||
| Q2 25 | 1.9% | 0.2% | ||
| Q1 25 | 1.3% | 0.2% | ||
| Q4 24 | 1.3% | 0.1% | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 3.2% | 0.1% | ||
| Q1 24 | 3.3% | 1.0% |
现金转化率ANIPRAMP
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 2.09× | ||
| Q2 25 | 8.87× | -2.04× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RAMP
暂无分部数据
